Gonadorelin (Factrel)
PeptideGonadorelin is a synthetic decapeptide identical to endogenous GnRH. FDA-approved as diagnostic agent for evaluating pituitary gonadotrope function. Also used therapeutically for hypogonadotropic hypogonadism via pulsatile pump. In males with HH, pulsatile GnRH achieves spermatogenesis in 85% (58/68 patients). Earlier spermatogenesis vs gonadotropin therapy (6 vs 14 months, p=0.01).
Quick Answer
What it is
Gonadorelin is a synthetic decapeptide identical to endogenous GnRH. FDA-approved as diagnostic agent for evaluating pituitary gonadotrope function.
Key findings
- Grade A: Diagnostic Accuracy (Hypogonadotropic Hypogonadism)
- Grade A: Spermatogenesis Induction (Hypogonadotropic Hypogonadism)
- Grade A: Testicular Growth (Hypogonadotropic Hypogonadism)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Gonadorelin (Factrel)
Quick Facts: Gonadorelin (Factrel)
- Best Evidence:Grade A
- Conditions Studied:1
- Research Outcomes:10
- Grade A Findings:4
- Key Effect:Hypogonadotropic Hypogonadism